A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

This study is open to adults aged 18 to 100 with certain types of advanced cancer that have spread or returned. To be considered, you would usually have already tried other cancer treatments. For example, some lung cancer patients must have had previous immunotherapy and chemotherapy, and their cancer must have shown some improvement from those treatments before getting worse.

For people with kidney cancer or melanoma, you would typically need to have tried both immunotherapy and another specific type of treatment, and your cancer must have progressed despite these previous treatments. If you have ovarian cancer (a specific type), you might be eligible if you haven't had immunotherapy before and have received one previous treatment for tricky-to-treat cancer.

Other specific cancers like breast cancer (a particular type), certain head and neck cancers, or cancers like anal cancer, mesothelimoa, or thymic cancer might also be eligible, often if you haven't had immunotherapy before or if other standard treatments have been tried. Your medical team will check all the details to see if this study is suitable for your specific situation.

If you decide to take part, you'll be given the study medication, KFA115 (either alone or with pembrolizumab), according to a schedule set by the study doctors. Because this is a Phase 1 study, the amount of KFA115 you receive might be slowly increased for new participants to find the safest dose. You will have regular visits to the clinic for medical check-ups, blood tests, and scans to monitor your health, side effects, and how well the treatment is working. The study will involve ongoing assessments for a period of time, followed by regular check-ins even after you stop taking the study medication to keep an eye on your health. The total duration of your participation could vary depending on how you respond to the treatment and the study's specific design, but you would be fully informed about the expected commitment.